Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study-Reference-Cited by-同舟云学术

Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study

Published:2022-07-19 Issue:3 Volume:12 Page:11-20
ISSN:2587-6813
Container-title:Malignant tumours
language:
Short-container-title:Malignant Tumours

Author:

Israelyan E. R.¹,Tryakin A. A.²,Rumyantsev A. A.²,Fedyanin M. Yu.³,Tyulyandina A. S.⁴,Protsenko S. A.⁵,Paichadze A. A.⁶,Bychkov Yu. M.⁷,Yunaev G. S.²,Tyulyandin S. A.²

Affiliation:

1. Pirogov Russian National Research Medical University; N. N. Blokhin National Medical Research Center of Oncology

2. N. N. Blokhin National Medical Research Center of Oncology

3. N. N. Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center «Kommunarka»

4. N. N. Blokhin National Medical Research Center of Oncology; I. M. Sechenov First Moscow State Medical University (Sechenov University)

5. N. N. Petrov Research Institute of Oncology

6. National Medical Research Radiological Centre

7. Russian Scientific Center of Roentgenoradiology

Publisher

Russian Society of Clinical Oncology

Subject

General Agricultural and Biological Sciences

Reference14 articles.

1. Gillesen S., Sauve N., Collette L. et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021;39 (14): 1563-1574. DOI: 10.1200/JCO.20.03296

2. Nichols C., Catalano P., Crawford E. et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16 (4): 1287-93. DOI: 10.1200/JCO.1998.16.4.1287

3. Tryakin A., Fedyanin M., Kanagavel D. et al. Paclitaxel + BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Urology. 2011;78 (3):620-5. DOI: 10.1016/j.urology.2011.05.005

4. Tryakin A., Fedyanin M., Sergeev U. et al. Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial. J Clin Oncol. 2015; 33 (suppl): abstr e15566. DOI: 10.1200/jco.2015.33.15_suppl.e15566

5. Droz J., Kramar A., Biron P. et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51:739–48. DOI:10.1016/j.eururo.2006.10.035